novocure(US:NVCR)2026-02-26 12:01Revenue and Growth - Net revenues are primarily derived from patients using the company's products, with potential net revenues per patient influenced by payment security, monthly fees, and duration of therapy [311]. - Net revenues increased by $50.1 million, or 8%, to $655.4 million for the year ended December 31, 2025, compared to $605.2 million in 2024 [343]. - The company reported net revenues of $655.4 million for the year ended December 31, 2025, an increase of 8.5% from $605.2 million in 2024 and 28.7% from $509.3 million in 2023 [386]. - Active patients at period end increased to 4,620 in 2025 from 4,126 in 2024, representing a growth of 12% [339]. - Prescriptions received in the United States rose to 4,183 in 2025 from 3,837 in 2024, an increase of 9% [340]. Expenses and Costs - Research, development, and clinical study expenses totaled $224.5 million in 2025, a slight increase from $209.6 million in 2024, with significant investments in clinical programs for solid tumors [316]. - The company incurred operating expenses primarily related to personnel costs, which are significant across research, development, sales, and general administration [313]. - Sales and marketing expenses are expected to remain significant as the company continues commercialization efforts in North America, the EU, and Japan [318]. - Cost of revenues increased by $29.7 million, or 22%, to $166.9 million in 2025, primarily due to a 9% growth in Optune Gio active patients [344]. - General and administrative expenses decreased by $12.2 million, or 6%, to $177.7 million in 2025, mainly due to lower share-based compensation [351]. Profitability and Financial Performance - Adjusted EBITDA decreased by $35.1 million to $(34.3) million for the year ended December 31, 2025, from $0.8 million in 2024, primarily due to increased operating expenses [356]. - The company experienced a net loss of $136.2 million for the year ended December 31, 2025, compared to a net loss of $168.6 million in 2024 and $207.0 million in 2023 [386]. - Income tax expenses decreased by $37.5 million, or 100%, resulting in a tax benefit of $0.0 million for the year ended December 31, 2025, compared to a tax expense of $37.5 million in 2024 [353]. - Financial income, net decreased by $21.8 million, or 55%, to $17.5 million for the year ended December 31, 2025, from $39.3 million in 2024 [352]. Cash Flow and Financial Position - As of December 31, 2025, the company had $93.5 million in cash and cash equivalents and $354.1 million in short-term investments, totaling $447.7 million, a decrease of $512.2 million compared to $959.9 million at the end of 2024 [358]. - Net cash used in operating activities was $49.0 million for the year ended December 31, 2025, compared to $26.4 million in 2024, an increase of $22.1 million [362]. - Net cash provided by investing activities was $437.3 million for the year ended December 31, 2025, compared to net cash used of $140.2 million in 2024, primarily due to net proceeds from short-term investments [366]. - Net cash used in financing activities was $451.3 million for the year ended December 31, 2025, compared to net cash provided of $90.3 million in 2024, mainly due to the repayment of a convertible note [368]. - The company has an accumulated deficit of $1,290.4 million as of December 31, 2025, reflecting significant losses since its founding [357]. Clinical Programs and Research - The company is prioritizing clinical programs with high value potential in glioblastoma, pancreatic cancer, and non-small cell lung cancer [317]. - The Phase 3 METIS clinical trial showed that patients treated with TTFields therapy and best supportive care experienced a 28% lower risk of intracranial progression compared to those receiving best supportive care alone [379]. - The median time to intracranial progression was 15.0 months for patients treated with TTFields therapy and best supportive care, compared to 7.5 months for those receiving best supportive care alone [379]. - The company has ongoing clinical trials, including Phase 3 trials in GBM and NSCLC, to explore the use of TTFields therapy [380]. - The company expects research, development, and clinical expenses to continue increasing over the next several years, potentially outpacing gross profit, indicating a need for additional capital [359]. Strategic Partnerships and Market Position - The company has established coverage policies with public and private payers for Optune Gio and is actively pursuing similar policies for Optune Lua and Optune Pax [378]. - The company has a license agreement with Zai Lab to commercialize its products in Greater China, aimed at accelerating the development of TTFields therapy [382]. - The company is in the final steps of adding production capacity in Mexico and Ireland to enhance supply chain resilience [384].